PNT2258

DRUG4 trials

Sponsors

Sierra Oncology LLC - a GSK company

Conditions

CancerLymphomaLymphoma, Diffuse Large B-CellLymphoma, Non-Hodgkin'sMelanomaProstate CancerRichter's Transformation

Phase 1

A Study of PNT2258 in Patients With Advanced Solid Tumors

CompletedNCT01191775

Sierra Oncology LLC - a GSK companyCancer, Lymphoma, Melanoma +1

Start: 2010-08-31End: 2012-04-30Updated: 2023-04-19

Phase 2

Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

CompletedNCT01733238

Sierra Oncology LLC - a GSK companyLymphoma, Non-Hodgkin's

Start: 2012-11-30End: 2016-08-31Updated: 2023-06-22

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

CompletedNCT02226965

Sierra Oncology LLC - a GSK companyLymphoma, Diffuse Large B-Cell

Start: 2014-12-31End: 2018-08-22Updated: 2023-06-29

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

TerminatedNCT02378038

Sierra Oncology LLC - a GSK companyRichter's Transformation

Start: 2015-08-31End: 2016-06-30Updated: 2023-06-29

Related Papers

A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies.

2021-07-234 citations

A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.

Journal of Clinical Oncology2016-05-204 citations

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Blood2014-12-0615 citations

Pharmacokinetics of the BCL2-targeted DNA interference (DNAi) nanoparticle PNT2258 in patients with recurrent or refractory non-Hodgkin lymphoma.

Journal of Clinical Oncology2014-05-201 citations

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma

Blood2013-11-155 citations